Every patent portfolio in the pharmaceutical industry contains dead weight. Not metaphorically — literally. Compounds whose commercial logic evaporated years […]

Launching a drug without a freedom-to-operate analysis is like building a factory on land you haven’t verified you own. You

How to Win Biopharma Contracts by Entering the Deal Before Generic Entry Does Why Timing Is the Only Thing That

The Number Every Pharma Strategist Gets Wrong Ask a pharmaceutical executive how long a drug patent lasts in Asia-Pacific, and

How generic drug suppliers’ litigation histories expose supply chain risk, financial fragility, and competitive staying power — before you sign

A practical playbook for formulation vendors, CDMOs, and excipient suppliers on how to mine patent loss-of-exclusivity data to find, time,

The $200 Billion Window Nobody in Sales Talks About Between 2025 and 2030, an estimated $200 billion in annual branded

How rare disease drugmakers build market protection that no generic can touch — and what every analyst needs to know

The Patent Cliff Is Not an Event. It’s a Calendar. Every biologic drug that ever earned blockbuster status is on